Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar

Eli Lilly's fourth-quarter earnings come as it tries to maintain its advantage over Novo Nordisk in the GLP-1 market.

By CNBC · CNBC

Eli Lilly's fourth-quarter earnings come as it tries to maintain its advantage over Novo Nordisk in the GLP-1 market.